Infliximab, a chimeric monoclonal antibody, inhibits TNF-α and has been approved for the treatment of inflammatory bowel diseases, psoriasis, psoriatic arthritis, ankylosing spondylitis, RA, and severe sarcoidosis.19 Here, TNF is linked to rheumatoid arthritis.